Abstract:e13514 Background: Comprehensive genomic profiling (CGP) is an important tool to identify actionable biomarkers and guide cancer therapy. However, patient (pt) race, socioeconomic status, and clinical setting are associated with lower access to CGP, targeted therapies, and clinical trials. To address this, we expanded a novel framework for genomic data management and clinical decision support developed at a large academic medical center to a network of affiliated community cancer centers located in rural, traditionally underserved communities. Methods: The Duke Precision Cancer Medicine Initiative (PCMI) developed a centralized database to aggregate and normalize CGP results. This database enables CGP review by a multi-disciplinary Molecular Tumor Board (MTB). PCMI established a protocol that allows the MTB to review CGP results and relevant clinical data for consented patients. This protocol opened enrollment at four DCN-affiliated cancer centers in rural North Carolina. Clinical recommendations are captured in a standard note and returned to DCN providers following each review. Our protocol also includes an anonymous survey sent to oncology providers asking about barriers to access and utilization of CGP. Results: Between Jan 2022 and Jan 2023, 62 pts were enrolled and had CGP results reviewed by the MTB; 13 pts (21.0%) were Native American and 20 (32.3%) were Black. 61 actionable genomic alterations were identified from 38 pts, including 16 (25.6%) that molecularly matched clinical trial inclusion criteria. Most DCN providers reported being comfortable ordering (14/20) CGP though fewer expressed comfort with interpretation (9/20) CGP; provider-reported barriers included cost/insurance for targeted therapies (12/20) and distance to clinical trials (14/20). Conclusions: Successful academic-community partnerships to expand access to CGP, clinical trials, and targeted therapies are feasible when supported by fit-for-purpose informatics tools and scalable workflows. Additional work is required to develop comprehensive solutions that ensure equal access to CGP and precision medicine for all patients. [Table: see text]

Genomic Answers for Kids: Toward more equitable access to genomic testing for rare diseases in rural populations

Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)

Overcoming barriers to equitable genomic healthcare

Exploring the journey to genomic testing and genetic services: A qualitative study of parental perspectives of children with rare conditions

Hospital-wide access to genomic data advanced pediatric rare disease research and clinical outcomes

Advancing diagnosis and research for rare genetic diseases in Indigenous peoples

Integrated multi-omics for rapid rare disease diagnosis on a national scale

Leaving no patient behind! Expert recommendation in the use of innovative technologies for diagnosing rare diseases

Implementing genomic medicine in clinical practice for adults with undiagnosed rare diseases

Project GIVE: using a virtual genetics service platform to reduce health inequities and improve access to genomic care in an underserved region of Texas

Rare disease genomic testing in the UK and Ireland: promoting timely and equitable access

The expanding diagnostic toolbox for rare genetic diseases

Rural-urban and racial-ethnic differences in awareness of direct-to-consumer genetic testing

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Rare genetic diseases in India: Steps toward a nationwide mission program

Overcoming barriers to adoption of precision medicine in community oncology centers in the rural southeastern United States using novel informatics tools and academic collaborations.

Clinical genome sequencing in patients with suspected rare genetic disease in Peru

Beyond the exome: what's next in diagnostic testing for Mendelian conditions

Experts' Views on Children's Access to Community-Based Therapeutic and Education Services After Genomic Sequencing Results

Socioeconomic and urban-rural disparities in genome-matched treatment receipt and survival after genomic tumor testing

Genome Sequencing for Diagnosing Rare Diseases